Background: The optimal management of elderly patients with non-ST-segment elevation myocardial infarction (NSTEMI) is still discussed. We aimed to study short-and long-term survival in NSTEMI patients ≥75 years managed with an invasive or a conservative strategy. Methods: NSTE-MI patients admitted to Oslo University Hospital Ulleval during 2005-2011 were included consecutively in a prospective registry. Vital status until December 31, 2013, was obtained from the Norwegian Cause of Death Registry. Patients ≥75 years were identified, and 30-day and 7-year survival were analyzed. Logistic-and Cox regression was used to estimate OR and hazard ratio (HR) for death in the invasive versus conservative group, adjusting for registered confounders. Results: There were 2,064 NSTEMI patients ≥75 years (48.2% women); 1,200 (58.1%) were treated with an invasive strategy, and were younger, more likely to be male and previously revascularized compared to 864 (41.9%) patients treat-ed conservatively (p < 0.0001 for all). Survival at 30-day was 94.9% in the invasive and 76.6% in the conservative group. For 30-day survivors, 7-year survival was 47.4% (95% CI 42.9-51.8) and 11.6% (95% CI 8.3-15.6), respectively. After multivariate adjustment, an invasive strategy was associated with lower long-term risk (adjusted HR [aHR] 0.49 [95% CI 0.41-0.59]). Actual revascularization was associated with lower risk of long-term mortality compared to angiography only (aHR PCI 0.73 [95% CI 0.59-0.90], aHR CABG 0.43 [95% CI 0.28-0.65]). Conclusion: In this real-life cohort of NSTEMI patients ≥75 years, 30-day survival was 95%, and 7-year survival was 47% with an invasive strategy. Revascularized patients had a superior long-term prognosis. With a conservative strategy, short-and long-term survival was lower, probably due to selection bias and unmeasured confounding.
Introduction
Several randomized controlled trials (RCTs) have demonstrated improved outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. DOI: 10.1159/000503442 managed with a routine invasive compared to a conservative strategy [1] [2] [3] . Guidelines from the American Heart Association/American College of Cardiology and the European Society of Cardiology recommend a routine invasive strategy in patients with NSTEMI without age restrictions [4, 5] . It is advised to consider benefits versus risks, including patient preferences, in older patients that are frail or have comorbid conditions with risk of adverse outcomes.
Elderly patients have been underrepresented in most RCTs performed, and outcome data in patients ≥75 years with NSTEMI are limited. Results from 2 smaller RCTs of invasive management in elderly patients with NSTEMI differed regarding a benefit of a routine invasive strategy [6, 7] . The larger after-80 study [8] , comparing an invasive versus a conservative strategy in 457 patients ≥80 years, showed a 47% risk reduction for the primary endpoint (a composite of myocardial infarction [MI], urgent revascularization, stroke, or death) with the invasive strategy, but no significant difference in all-cause mortality [8] . In a large observational study including octogenarians with unstable angina or NSTEMI, an invasive strategy (≤48 h) was associated with lower in-hospital mortality, but higher risk of cardiogenic shock [9] . Other observational studies have shown a favorable prognosis up to 1 year with an invasive strategy for elderly NSTEMI patients [10, 11] , but long-term data are lacking. Due to the sparse data from clinical trials as well as from the realworld setting, the optimal management strategy for older patients with NSTEMI remains a subject of debate. The aim of the present study was to study short-and longterm survival in a cohort of NSTEMI patients ≥75 years admitted to a cardiac center in Norway and managed with an invasive or a conservative strategy.
Methods

Study Population
This was an observational cohort study using data registered prospectively in the Oslo University Hospital (OUH) Ulleval MI registry. OUH Ulleval is a community hospital for 190,000 inhabitants and serves as a tertiary cardiac center for the region of Eastern Norway with a catchment population of 1,400,000 people. From September 1, 2005, all consecutive patients with acute MI (AMI) admitted to our hospital were prospectively recorded in a local registry. The diagnosis of AMI was made according to the current AMI definition [12, 13] , using troponin T as the cardiac biomarker. Classification of ST-segment elevation MI or NSTEMI was based on the diagnostic electrocardiogram [14] . The inclusion to our local registry closed on December 31, 2011, due to the establishment of a national MI registry in Norway with a different owner.
In the present study, only the first admission for NSTEMI during the study period was included. The study population flow chart is presented in Figure 1 . Patients aged ≥75 years with NSTEMI were divided in 2 groups: (1) the invasive group defined as patients who underwent coronary angiography during the index hospitalization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) if indicated, in addition to recommended medical therapy and (2) the conservative group receiving recommended medical therapy only. Therapeutic decisions were solely at the discretion of the treating physician. Reasons for using an invasive or conservative strategy were not recorded in the registry.
Data Collection, Definition of Variables, and Validation
Data regarding baseline cardiovascular risk factors, treatment, invasive procedures, coronary angiograms, in-hospital complications, and in-hospital mortality were registered in an electronic database developed by the Mid-Norway Health Authority as described previously [14] . Variables were predefined in the OUH Ulleval MI registry user manual [15] . Coronary angiograms were described as normal if no visible atherosclerotic lesions, as nonobstructive coronary artery disease (CAD) if < 50% stenosis, or as significant CAD if ≥50% stenosis were present. One-vessel disease was defined as significant CAD in one vessel, and multiple vessel disease as the presence of significant CAD in > 1 coronary arteries or in the left main coronary artery.
An internal validation procedure of the variables registered for 200 random patients was performed by the primary investigator. Values were compared with the patients' hospital records, and the estimated correlation between registry data and patient records was > 90%. The continuous variable serum (s)-creatinine at admission had 10.6% missing values, and a sensitivity analysis was performed with normal (defined as 70 µmol/L) or high (defined as 300 µmol/L) values replacing missing values. For all other included variables, missing values were < 5%.
Follow-Up and Outcomes
Vital status until the end of follow-up on December 31, 2013, was obtained by linkage to the Norwegian Cause of Death registry. Follow-up time was defined as time from hospital admission to death or end of follow-up, whichever came first, and differed between patients due to the dynamic inclusion period. No information was available with respect to treatment after discharge from the index hospital admission.
Two primary analyses were performed. In the first, the primary endpoint was 30-day survival. In the second, the primary endpoint was survival during maximum 7 years of follow-up in patients being alive at day 30 after admission (a so-called landmark analysis) [16] . Secondary endpoints were OR for the association between an invasive strategy and 30-day mortality, and hazard ratio (HR) for mortality during follow-up among 30-day survivors in the invasive compared to the conservative group. In the landmark analysis of patients surviving the first 30 days, follow-up time was defined from day 30 to end of follow-up.
Ethics
The establishment of the local MI registry and the conduction of this study were approved by the Privacy Protection Officer at OUH. The Ministry of Health and Care Services approved exemption from the duty of confidentiality (November 16, 2011) and The Norwegian Data Protection Authority provided concession for data linkage with the Norwegian Cause of Death Registry (January 5, 2012). All data were anonymized before analysis.
Statistical Analysis
Categorical variables are reported by numbers and percentage, after removing missing values (denominators may vary). Continuous variables are reported by mean ± SD or median (25-75th percentile). Differences between the invasive and conservative groups in baseline risk factors and complications were tested with chisquare or Fisher exact tests for categorical variables and 2-sample t test or Mann-Whitney U test for continuous variables, as appropriate. Survival from admission to day 30 and 7-year survival from day 30 were calculated with the life-table method and illustrated with the Kaplan-Meier survival function. Survival functions were compared with the log-rank test. Patients in the invasive group were considered as the exposed, while patients in the conservative group were the non-exposed. Logistic regression was used to calculate OR with 95% CI for the association between exposure and 30-day mortality. Based on previous knowledge [17] [18] [19] [20] [21] [22] [23] and clinical considerations, the following covariates were included to adjust for confounding: age, gender, previous hypertension, previous MI, previous revascularization, previous stroke, diabetes mellitus, peripheral artery disease, s-creatinine at admission, out-of-hospital resuscitation, heart failure, cardiogenic shock, atrial fibrillation/ -flutter, and antibiotic treatment. Cox regression was used to calculate HR with 95% CI for long-term mortality after 30 days in the exposed versus non-exposed. The proportional hazards assumption was evaluated using the log-log Kaplan-Meier plot. Confounding adjustment was as in the logistic regression. Pre-specified analyses for effect modification by age, gender and s-creatinine were performed by forcing an interaction term into the multivariate regression models, one at a time. As the primary analyses were significant, subgroup analysis of survival among patients in the invasive group treated with PCI, CABG or no revascularization was performed [24] . All tests were two-tailed, and a p value < 0.05 was considered significant. Analyses were performed with STATA 13 (Statacorp LP, TX, USA). The study confines with the STrengthening the Reporting of OBservational studies in Epidemiology checklist for reporting of observational studies [25] .
Results
Study Population
Among 5,159 NSTEMI patients admitted to our hospital during 2005-2011, 2,064 patients (40.0%) were ≥75 years and constitute the study cohort ( Fig. 1 indicated (invasive group), and 864 patients (41.9%) received recommended medical therapy only (conservative group). The median time from symptom onset to coronary angiography was 3 [2] [3] [4] [5] days. Patients in the invasive group were younger, more likely to be men and previously revascularized, and less likely to have had a previous stroke and elevated s-creatinine at admission (Table 1) . 
Revascularization and In-Hospital Complications
In the invasive group, 1,057 patients (88.1%) had significant one-or multiple-vessel CAD, and 706 patients (58.8%) were treated with PCI or CABG ( Table 2 ). In the conservative group, by definition, no coronary angiography was performed during the index hospitalization. The proportion of patients with out-of-hospital resuscitation, cardiogenic shock, and in-hospital arrhythmias were similar in both groups (Tables 1, 2 ). Compared to the conservative group, patients in the invasive group were less likely to have atrial fibrillation/flutter, heart failure, stroke, and antibiotic treatment during the hospital stay ( Table 2) .
Outcomes
During the first 30 days, 60/1,200 (5.0%) of patients treated invasively died and 199/864 (23.0%) in the conservative group (Table 3, Fig. 2 ). Among patients who survived the first 30 days (n = 1,805), median follow-up time was 1,155 days (634-1,687), and maximum follow-up time was 2,974 days. Estimated 7-year survival was 47.4% in the invasive group and 11.6% in the conservative group (Table 3 , Fig. 3 ). After multivariate adjustment, an invasive strategy was associated with 51% lower risk of death during follow-up compared to a conservative strategy (Table 4 ). The proportional hazards assumption was considered valid.
There was effect modification by level of s-creatinine at admission on the association between an invasive strategy and long-term mortality (p interaction = 0.006). When patients were dichotomized according to s-creatinine levels (< 110 or ≥110 µmol/L), the effect was larger for patients with s-creatinine < 110 µmol/L at admission (adjusted HR [aHR] 0.45 [95% CI 0.38-0.54]) than for patients with s-creatinine ≥110 µmol/L (aHR 0.64 [95% CI 0.47-0.87]). There was no significant effect modifica-tion by age (p = 0.166) or gender (p = 0.791). In a sensitivity analysis, there were no alteration of the association between s-creatinine and mortality in the Cox regression model. Therefore, we assumed that s-creatinine values were missing completely at random.
In a subgroup analysis of patients treated invasively, 30-day survival was similar for patients undergoing angiography only and for those revascularized with PCI or CABG (p = 0.125; Fig. 4a ). Revascularization with PCI or CABG was not independently associated with 30-day survival after adjustment for age and other baseline charac- After 30-days, estimated 7-year survival was 43.7% (95% CI 37.2-50.1) for patients with angiography only (n = 467), 55.1% (95% CI 49.0-60.8) with PCI (n = 544), and 67.5% (95% CI 55.4-77.0) with CABG (n = 125; Fig. 4b ). After 30 days, actual revascularization with PCI or CABG was associated with lower risk of long-term mortality, also after multivariate adjustment (aHR PCI 0.73 [95% CI 0.59-0.90], p = 0.003 and aHR CABG 0.43 [95% CI 0.28-0.65], p < 0.0001). The PH-assumption was regarded valid.
Discussion
In this observational study of patients with NSTEMI aged ≥75 years, the main findings were (1) 30-day survival was near 95%, and 7-year survival was almost 50%, with the use of an invasive strategy. (2) Short-and longterm survival in the conservative group were lower, with a 30-day survival of 77%, and 7-year survival of only 12%.
(3) Among invasively treated patients, revascularization with PCI or CABG was associated with improved longterm survival compared to angiography only.
To our knowledge, this is the first study to document survival exceeding 1 year for NSTEMI patients ≥75 years treated with an invasive strategy. In line with our results, previous studies have reported in-hospital mortality ranging from 4 to 6% for invasively treated versus 7-11% for conservatively treated elderly patients with NSTE-ACS [9, 11] . Among 1,936 NSTEMI patients ≥75 years, 1-year mortality was 10.7% for invasively versus 27.9% for conservatively treated [10] . In a pooled analysis from the FRISC-II, Conservative Treatment in Unstable Coronary Syndromes and RITA-3 (FIR) trials, 5-year cardiovascular mortality for elderly NSTE-ACS patients was only 18.5% [3] . The diverging results of mortality in observational cohorts and RCT's, suggest selection of healthier, lower-risk patients for RCTs than in real-life clinical practice. The problem in the present study was a selection of patients considered for an invasive strategy, both in community hospitals and in the tertiary center. Selection bias can result in overestimation of survival rates or the effect of an intervention. Since this was a registry based on clinical practice, the therapeutic strategy was at the physician's discretion, and no specific exclusion criteria were applied for invasive treatment. The lack of specific criteria for therapeutic strategy might limit the external validity and generalizability of our results. Furthermore, patients in our study were treated in 2005-2011, before wide use of 2nd generation drug-eluting stents, newer antiplatelet agents and catheterization techniques and survival rates may not be generalizable to all elderly NSTEMI patients.
Although RCTs are the gold standard for evaluating the effect of interventions, including elderly patients in clinical trials may be difficult, and RCTs of invasive treatment in elderly patients have been terminated prematurely due to slow recruitment [26] . Therefore, results from observational studies with high internal validity can provide important knowledge reflecting clinical practice for elderly patients underrepresented or excluded from clinical trials [27] .
As expected, patients treated invasively in our study were younger (mean age 80.4 vs. 86.4 years). They were more likely men and had a higher percentage previous revascularization, but less often had a previous stroke. These factors are associated with risk of CAD and adverse outcomes in the setting of ACS [28, 29] . Other known prognostic factors, such as bleeding history or anaemia [29] , were not registered in this study, but may have influenced the treatment decision and outcomes in this elderly cohort. Diabetes, hypertension, and peripheral artery disease were similar for patients treated invasively or conservatively [30] . The fact that higher risk elderly AMI patients are not treated invasively is described as the "age-risk paradox" [31] , that is, the advantage of PCI increases with background risk, but that increased background risk results in a patient not being revascularized. Complicating observational studies of elderly patients, it may be the presence of contraindications to coronary angiography or PCI (and thus another disease), that account for the increased mortality risk, and not the conservative strategy itself [32] . Comorbidities such as cancer, liver disease, dementia, or chronic obstructive pulmonary disease and life expectancy should be considered [4] in the choice of treatment strategy. Previous studies of elderly patients with AMI or NSTE-ACS have reported lower prevalence of comorbidities among invasively compared to conservatively treated (chronic obstructive pulmonary disease 10-18 vs. 13-26%, cancer 6 vs. 12%, and dementia 5 vs. 18%, respectively) [9, 33] . Frailty can be defined as an age-related vulnerability to a stressor event, increasing the risk of adverse outcomes [34] . Mortality risk is increased among frail compared to non-frail elderly AMI patients, independent of chronological age and clinical risk scores [35] [36] [37] [38] . Unfortunately, these factors were not registered in the present study and could therefore not be adjusted for in the risk estimates.
Patients treated invasively had lower levels of s-creatinine at admission compared to patients treated conser-Cardiology 2019;144:79-89 DOI: 10.1159/000503442 vatively. Our finding of effect modification by level of s-creatinine suggests the invasive strategy to be less effective in elderly NSTEMI patients with renal dysfunction. This corresponds to findings that moderate to severe renal dysfunction is associated with mortality among invasively treated AMI patients [20] . There is a need for more knowledge about the influence of an invasive strategy in elderly NSTEMI patients with renal dysfunction.
The association between actual revascularization with PCI or CABG and improved long-term survival may be less influenced by selection bias. Reasons for not performing PCI or CABG were unfortunately not registered in our study, and factors such as non-obstructive coronary lesions, unsuitable coronary anatomy, technical difficulties, or per-procedural complications may have influenced long-term survival. In line with our results, a per-protocol analysis from the Invasive versus Conservative Treatment in Unstable Coronary Syndromes trial [39] found that actual revascularization was associated with reduced 4-year mortality among NSTE-ACS patients, as opposed to the original intention-to-treat analysis that was neutral [24] .
Our study describes better survival for elderly NSTE-MI patients clinically selected for an invasive strategy compared to conservative strategy. However, the study was not designed for determining a treatment effect, and selection bias and confounding factors may account for the observed difference in risk and survival between groups. Patients that were revascularized had a better long-term prognosis. The proportion of elderly patients treated with an invasive strategy was quite low (only 48%), as in previous studies of elderly NSTE-ACS patients [9] [10] [11] . However, a total of 59% of NSTEMI patients ≥75 years treated with an invasive strategy were revascularized. For comparison, 67% of invasively treated in the total cohort of NSTEMI patients during 2005-2011 from our center (all ages) received actual revascularization [40] . One can speculate that more elderly NSTEMI patients could benefit from an invasive strategy with revascularization. With the higher life expectancy and growth of the elderly population, an evidence-based strategy on how to treat elderly patients with NSTEMI is essential [8] . Adequately powered RCTs for mortality after an invasive versus conservative strategy in elderly AMI patients are wanted. Awaiting this, more descriptive studies are needed of prognostic factors both for treatment decisions and long-term survival to better anticipate the best treatment for complex, high-risk individuals, often found among elderly patients.
Strengths and Limitations
The strengths of our study are long-term survival estimates for a large, consecutive NSTEMI cohort ≥75 years reflecting clinical practice. The subgroup analysis of actual revascularization differentiates between patients selected for an invasive strategy based on clinical features and shows a strong association between treatment and long-term survival for elderly NSTEMI patients. The landmark analysis of survival after 30 days was performed to reduce immortal time bias [41] , that is, bias due to acute illness severity with death before coronary angiography could be performed.
The main limitation of our study was the observational design with a physician selection of patients for invasive or conservative strategy. The treatment decision was not registered. Unmeasured confounding may have influenced the treatment strategy and survival. Heart rate, blood pressure, left ventricular ejection fraction, medications after discharge, and compliance were not registered. With the emergence of high-sensitivity cardiac troponin assays and increasing awareness that reference values may be different for women and men, diagnostic sensitivity for NSTEMI may have changed since the study period [42] . In the future, characteristics of clinical NSTEMI cohorts may potentially alter due to enhanced diagnostic accuracy and risk stratification by added biomarkers, that is, growth differentiation factor-15, natriuretic peptides, copeptin, or heart-type fatty acid-binding protein [43] [44] [45] .
Revascularization or cardiac rehabilitation during follow-up may have influenced long-term survival. Noncardiovascular causes of death may influence long-term survival [40] , especially in elderly cohorts. End points such as burden of symptoms, hospital readmissions, or quality of life during long-term follow-up are all important outcomes, which should be included in future studies.
This study was conducted in a university hospital, being a combination of a community hospital and a tertiary cardiac center, and the results are not necessarily generalizable to all elderly NSTEMI patients. Despite our efforts to convey bias by prospective registration, landmark analysis, and controlling for confounders, a causal effect of an invasive strategy on survival in elderly NSTEMI patients cannot be inferred. DOI: 10.1159/000503442
Conclusion
In this real-life cohort of NSTEMI patients ≥75 years, 30-day survival was 95%, and 7-year survival was 47% with an invasive strategy. Revascularized patients had a superior long-term prognosis. Short-and long-term survival with a conservative strategy was significantly lower, probably due to selection bias and unmeasured confounding.
